Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 47%
Hold 11%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly's stock outlook is positively influenced by robust growth across several key business segments, with cardiovascular revenues increasing by 16.1% year-over-year in Q4, underscoring strong demand for its cardiometabolic products. The company's leadership in the electrophysiology market, highlighted by a remarkable 35% organic growth, positions it well for future expansion, especially with market forecasts predicting a 15% annual growth rate through 2026. Additionally, the neuromodulation segment also exhibited solid performance with a 10% year-over-year organic revenue increase, contributing to a diversified and resilient portfolio amidst an evolving healthcare landscape.

Bears say

Eli Lilly's stock outlook is negatively impacted by an 18% decline following guidance for 2026 that fell short of consensus expectations, compounded by perceived weaknesses in the Electrophysiology (EP) segment. Financial risks include potential pricing pressures, lackluster uptake of key products such as tirzepatide (Mounjaro), and higher debt levels stemming from recent mergers and acquisitions, which may hinder the company's operational leverage. Additionally, competition and potential underperformance in product launches further elevate the downside risks to Lilly's financial stability and growth trajectory.

Eli Lilly (LLY) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 47% recommend Buy, 11% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 19 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,182.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,182.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.